{"classes":[{"categories":[{"measurements":[{"comment":"Here, 'NA' signifies that Median and upper limit of 95% CI could not be estimated due to an insufficient number of participants with events.","groupId":"OG000","lowerLimit":"56.74","upperLimit":"NA","value":"NA"},{"comment":"Here, 'NA' signifies that Median, lower limit and upper limit of 95% CIcould not be estimated due to an insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"description":"Duration of CHR was defined as the time between the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive diseased. CHR was primarily defined by negative immunofixation results and normalized FLC parameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dexamethasone (40 mg weekly dose)starting from cycle 1 day1 in every 28-day cycle followed by cyclophosphamide 300 mg/m\\^2 orally or IV maximum weekly dose 500 mg and then bortezomib 1.3 mg/m\\^2 SC injection once weekly up to 7.33 months. All cycles were of 28 days. After completion of treatment phase participants entered into the post treatment observation phase and were continued with disease evaluations every 8 weeks post last dose up to disease progression (up to 6.5 years). Participants then entered into long term follow up phase and were followed up for survival every 16 weeks (up to 7.1 years).","id":"OG000","title":"CyBorD"},{"description":"Participants received combination therapy for six cycles of 28 days each, daratumumab 1800 mg SC weekly starting from cycles 1 day 1 and cycle 2, every 2 weeks in cycles 3 through 6, dexamethasone 40 mg weekly (on days of daratumumab dosing, dexamethasone was split, 20 mg as premedication and 20 mg as post daratumumab dosing), cyclophosphamide 300 mg/m\\^2 orally or IV maximum weekly dose 500 mg, bortezomib 1.3 mg/m\\^2 SC injection once weekly. After 6 cycles, participants continued to receive daratumumab SC monotherapy until disease progression, start of subsequent therapy or up to 26.71 months from the first dose of study treatment. All cycles were of 28 days. After completion of treatment phase participants entered into the post treatment observation phase and were continued with disease evaluations every 8 weeks post last dose up to disease progression (up to 6.5 years). Participants then entered into long term follow up phase and were followed up for survival every 16 weeks (up to 7.1 years).","id":"OG001","title":"Daratumumab Plus CyBorD"}],"paramType":"MEDIAN","populationDescription":"Responders in intent-to-treat analysis set included all randomized participants. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Data for this outcome measure was planned to be collected and analyzed for specified arms only.","reportingStatus":"POSTED","timeFrame":"From date of first randomization (Day -3) up to 6.5 years","title":"Duration of Complete Hematologic Response (CHR)","type":"SECONDARY","unitOfMeasure":"Months"}